The Overlap Between IBS and SIBO, and the Breath-Test Caveats

Are IBS and SIBO actually two different things?

They are two different kinds of claim, which is why they refuse to line up neatly. SIBO names a proposed cause — excessive bacteria in the small intestine, producing gastrointestinal symptoms 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the acknowledged limitations of breath-test diagnosis, and the conditional (rather than strong) recommendation for antibiotics in symptomatic SIBO.. IBS names a pattern, measured against a published set of symptom criteria 2Ref 2The Rome Foundation (2016).Rome IV Criteria.That IBS is defined by Rome IV — an expert-consensus, symptom-based diagnostic framework for disorders of gut-brain interaction — rather than by a laboratory finding.. One is a mechanism. The other is a description. Nothing prevents a person from satisfying both at once, and many people do.

Once you see that, the either-or shape of the question falls apart. Asking whether it is IBS or SIBO is a little like asking whether a cough is bronchitis or a cough. The categories were not built on the same axis, so they were never going to partition cleanly into two doors.

IBS describes what your gut is doing. SIBO proposes why. A proposed why does not cancel an accurate what.

This is not an argument that SIBO is fake. It has an American College of Gastroenterology guideline of its own, which is not something wellness inventions tend to acquire 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the acknowledged limitations of breath-test diagnosis, and the conditional (rather than strong) recommendation for antibiotics in symptomatic SIBO.. It is an argument that the boundary between the two is genuinely blurred, that the blur is acknowledged inside the guidelines rather than hidden from patients, and that a great deal of confident internet content is built on pretending otherwise.

What SIBO is, and what the label is quietly doing

The ACG defines SIBO as an excess of bacteria in the small bowel that is causing gastrointestinal symptoms 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the acknowledged limitations of breath-test diagnosis, and the conditional (rather than strong) recommendation for antibiotics in symptomatic SIBO.. Read that definition slowly, because it has two halves and the second half is the one that gets dropped. Bacteria alone are not SIBO. Symptoms alone are not SIBO. The diagnosis requires both, joined by a causal claim — and that causal claim is exactly the part a test cannot hand you.

SIBO stands for small intestinal bacterial overgrowth. The small bowel is meant to be relatively sparse in bacteria compared with the colon; the overgrowth is the proposal that in some people it is not.

That two-part structure matters at the moment a result comes back. An abnormal test in someone with no symptoms does not meet the small intestinal bacterial overgrowth definition — it is a number without the thing the number is supposed to explain. And an abnormal test in someone who does have symptoms establishes association, not cause. The symptoms could be produced by the bacteria. They could equally be produced by whatever else was already producing them, with an unrelated test result sitting alongside.

The honest version of sibo, honestly, is that it is a real proposed entity with a real guideline, a contested threshold, and an unresolved relationship to the much larger population of people whose symptoms are called IBS. Anyone telling you it is simpler than that is selling the simple version.

Why the breath test cannot settle it

The breath test is where this question is usually decided, and it is the weakest link in the chain. The ACG guideline addresses breath-test diagnosis together with its limitations rather than presenting it as definitive 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the acknowledged limitations of breath-test diagnosis, and the conditional (rather than strong) recommendation for antibiotics in symptomatic SIBO.. That framing is the tell. Guidelines do not attach a limitations discussion to instruments that work cleanly.

The mechanics explain why. You drink a sugar solution. Bacteria ferment it and produce gas. Some of that gas crosses into your blood and comes out in your breath, where it gets measured over the following hours. Nothing in that sequence looks at your small intestine. The test infers location from timing — early gas is read as small-bowel bacteria, later gas as the colon — and timing is a proxy, not a picture.

Proxies fail in both directions, which is the part worth internalising:

• A fast transit time moves the sugar to the colon early. Normal colonic bacteria then ferment it on schedule, and the gas arrives inside the window that gets scored as small-bowel. That is a SIBO breath test false positive produced by ordinary physiology.
• A slow transit time can push real small-bowel fermentation outside the window, and the test reads normal in someone the label would actually fit.
• The scored thresholds are a matter of consensus rather than of nature, so the same breath can be positive under one protocol and negative under another.

None of this makes the test worthless. It makes it a piece of evidence with real sibo breath test limits, which a clinician weighs against everything else — and not a verdict that overrides a symptom history. Breath tests are also not one instrument: testing for h. pylori uses a breath test built on a completely different principle, and its performance says nothing about this one. Fructose malabsorption is assessed with a test from the same family, and inherits the same interpretive caution.

Why getting better on the antibiotic proves nothing

This is the inference that traps almost everyone, and it is worth taking apart carefully. The reasoning runs: I took rifaximin, I improved, therefore the bacteria were the problem, therefore I had SIBO. It feels airtight. It is not, and the trial that broke it is one of the best-known studies in the field.

The TARGET trials tested a two-week course of rifaximin against placebo in people with IBS without constipation — people enrolled on their IBS symptoms, not selected for SIBO and not required to have a positive breath test. The drug produced modest but statistically significant relief of global symptoms and bloating compared with placebo 3Ref 3Pimentel M, Lembo A, Chey WD, et al. (TARGET Study Group) (2011).Rifaximin therapy for patients with irritable bowel syndrome without constipation.That the phase 3 TARGET trials gave a two-week rifaximin course to patients enrolled on IBS-without-constipation symptoms rather than on a SIBO diagnosis, and found modest but significant relief of global symptoms and bloating versus placebo.. The ACG's IBS guideline reflects that result by placing rifaximin on the shelf for IBS with diarrhea 4Ref 4Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That ACG recommends a positive diagnostic strategy for IBS with targeted rather than exhaustive testing, and that IBS treatment is organized by subtype, with rifaximin recommended for IBS with diarrhea..

An antibiotic that helps people who were never tested for SIBO cannot be run backwards into a test for SIBO.

So improving on rifaximin puts you in a large, well-documented group: people with IBS who respond modestly to rifaximin. It does not sort you into the SIBO subset of that group, because the trial demonstrating the benefit did not sort anyone that way either. The response is real. The conclusion drawn from it is not licensed.

The same logic disarms the mirror-image worry. If you took the antibiotic and nothing changed, that is not evidence your symptoms were imaginary or that you failed the treatment. The benefit in the trials was modest, which is the honest word for it — a meaningful improvement for some people, and no improvement at all for many others. Where any of this sits among prescription medications for ibs is a question of subtype rather than of proving a hidden infection.

What the two labels share, and where they diverge

The overlap is not incidental — it is most of the picture. Bloating is the clearest example, and it is usually the symptom that sends people looking for SIBO in the first place. The AGA notes that bloating and distention are frequently associated with IBS and with other disorders of gut-brain interaction, and that management can include dietary change, brain-gut behavioural therapies, and neuromodulators 5Ref 5Moshiree B, Drossman D, Shaukat A (2023).AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.That bloating and distention are frequently associated with IBS and other disorders of gut-brain interaction, and that management may include dietary change, brain-gut behavioral therapies, and neuromodulators.. A symptom shared by both candidates cannot arbitrate between them.

Where they genuinely diverge is in what each opens up next. IBS sorts into subtypes — with constipation, with diarrhea, and a mixed type that swings between them — and the subtype drives most of what gets tried 6Ref 6National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2017).Symptoms & Causes of Irritable Bowel Syndrome.That IBS symptoms vary by type — IBS with constipation, IBS with diarrhea, and a mixed type — and the description of common IBS symptoms.. That is a working ladder. A SIBO label, by contrast, tends to open a loop: test, treat, retest, relapse, retest. Notice that the ACG recommends antibiotics for symptomatic SIBO only conditionally 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the acknowledged limitations of breath-test diagnosis, and the conditional (rather than strong) recommendation for antibiotics in symptomatic SIBO.. Conditional is guideline language for the evidence being thin enough that reasonable clinicians will disagree — and it is a strange foundation for a diagnosis people are asked to reorganise their lives around.

The differential has more than two doors

Framing the question as IBS or SIBO narrows the field to two candidates before anyone has established that the field is that small. Several other conditions live in the same overlap of bloating, pain, and altered bowel habit, and none of them is settled by a breath test. They get missed precisely because IBS is such a comfortable landing place — once the label is applied, the search tends to stop.

• Celiac disease. It has a defined diagnostic pathway of its own. The sequencing is what catches people out, which is why ibs versus celiac is worth raising before any elimination diet removes wheat from the picture.
• Endometriosis. Cyclical pelvic and bowel symptoms are readily filed under IBS, particularly given that IBS is diagnosed on symptoms alone. The endometriosis IBS overlap is a well-recognised source of long diagnostic delays.
• Carbohydrate malabsorption. Fructose malabsorption produces a symptom set that reads as IBS and as SIBO simultaneously.

The point is not to hand you a longer list to worry about. It is that a positive breath test is not a stopping condition. If your symptoms are being explained by something outside these two labels, the SIBO result will not tell you — it was never looking.

What actually moves this forward

The productive move is to stop trying to win the naming argument and start working the ladder that exists. The ACG recommends that IBS be diagnosed positively — from the pattern, with testing targeted at what your specific presentation raises — rather than assembled from a pile of normal results 4Ref 4Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That ACG recommends a positive diagnostic strategy for IBS with targeted rather than exhaustive testing, and that IBS treatment is organized by subtype, with rifaximin recommended for IBS with diarrhea.. That approach absorbs the SIBO question rather than being blocked by it, because the treatments worth trying are largely the same either way.

Bring the history, not the result. How long, what the pain does around bowel movements, what your stool form has been doing, what you have already cut and what happened. A breath-test printout without that context is a number no one can interpret.

Ask what a positive result would change. This is the single most clarifying question available, and it is fair to ask directly. If the answer is a two-week antibiotic course that the IBS guideline would have offered on your symptom pattern anyway 3Ref 3Pimentel M, Lembo A, Chey WD, et al. (TARGET Study Group) (2011).Rifaximin therapy for patients with irritable bowel syndrome without constipation.That the phase 3 TARGET trials gave a two-week rifaximin course to patients enrolled on IBS-without-constipation symptoms rather than on a SIBO diagnosis, and found modest but significant relief of global symptoms and bloating versus placebo. 4Ref 4Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That ACG recommends a positive diagnostic strategy for IBS with targeted rather than exhaustive testing, and that IBS treatment is organized by subtype, with rifaximin recommended for IBS with diarrhea., the test did not steer anything.

Ask what happens when it comes back. Recurrence is the norm in the SIBO story, and a plan that consists of repeating the same course indefinitely deserves scrutiny before you start, not after the third round.

Being told your symptoms are IBS rather than SIBO is not being told you have nothing. IBS has criteria, subtypes, and a treatment ladder with evidence under it — which is more than the alternative label currently offers.

The strongest reason to care about this framing is practical. Time spent litigating which label is correct is time not spent on the dietary, behavioural, and pharmacological options that both guidelines point toward regardless of which one wins 4Ref 4Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That ACG recommends a positive diagnostic strategy for IBS with targeted rather than exhaustive testing, and that IBS treatment is organized by subtype, with rifaximin recommended for IBS with diarrhea. 5Ref 5Moshiree B, Drossman D, Shaukat A (2023).AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.That bloating and distention are frequently associated with IBS and other disorders of gut-brain interaction, and that management may include dietary change, brain-gut behavioral therapies, and neuromodulators..